Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management, has signed an agreement for clinical development services with Parexel International. Parexel’s Biotech division will conduct a Phase I study to evaluate the bioavailability of TABMELT technology and provide regulatory support for Vivera’s IND process with the U.S. FDA. “We are thrilled to partner with Parexel’s dedicated Biotech team on this important clinical program. Par...